Search our site 
Advanced Search
Home | Exam dates | Contact us | About us | Testimonials |

You are in Home >> Intensive Care >> Sepsis >> Metabolic & Cytokine Therapies >> Potential therapies: Literature

Bernard et al. The PROWESS trial. NEJM 2001

Created: 17/5/2007

Paper type

Randomised Controlled Trial


Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
New England Journal of Medicine 2001; 344: 699-709.

Major Finding

For every 16 patients with sepsis given activated protein C, compared to placebo, one less patient dies. The risk of bleeding complications may be increased.

Point for discussion:

As a result of the extensive correspondance relating to this and the subsequent APC trials are ICU clinicians as keen to prescribe APPC as they were when this study was first reported?

SiteSection: Article
  Posting rules

     To view or add comments you must be a registered user and login  

Login Status  

You are not currently logged in.
UK/Ireland Registration
Overseas Registration

  Forgot your password?

All rights reserved © 2021. Designed by AnaesthesiaUK.

{Site map} {Site disclaimer} {Privacy Policy} {Terms and conditions}

 Like us on Facebook